Betagenon AB

Sweden
Umeå, Västerbotten, Sweden, 907 36

Company profile

Betagenon AB company profile

Betagenon is a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Drugs that activate AMPK are expected to have beneficial effects on metabolic and cardiovascular diseases and on certain cancers. Their lead AMPK activator compound O304 is currently in Phase IIa clinical trial.

Business identity

Contact email
[email protected]
Phone number
+46 90154822
Operating status
Closed
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2001-01-01, Year

Headquarters

Postal code
907 36
Country code
SE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
2
Total equity funding
$2M
Last funding
Series Unknown / $2M / 2021-06-02
Last equity funding
Series Unknown / $2M
Investors
1
Founders
1
Articles
2
Closed on
2023-03-14
Exited on
2023-03-14

Founders and investors

Founders

Thomas Edlund

Investors

EISMEA